Acumen Pharmaceuticals, Inc. (ABOS) Form 10-Q — May 12, 2026
Acumen Pharmaceuticals reported a narrower net loss of $20.7 million for the quarter ended March 31, 2026, compared to $28.8 million in the prior year, driven primarily by reduced manufacturing and CRO costs associated with its ALTITUDE-AD clinical trial. Despite the improved financial performance, the company raised substantial doubt about its ability to continue as a going concern, stating that current cash and marketable securities of $128.4 million are only expected to fund operations into early 2027.
Key figures
- Total Debt
- 31047
- Cash Position
- 128398
- Shares Outstanding
- 72227580
- Private Placement Gross Proceeds
- 35700
- Research And Development Expenses
- 16484
- General And Administrative Expenses
- 4665
Price after filing
Close on the filing date to close N calendar days later (from $2.48). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.